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Abstract
Aims/hypothesis Beta cells situated in the islet of
Langerhans respond more vigorously to glucose than do
dissociated beta cells. Mechanisms for this discrepancy
were studied by comparing insulin-producing MIN6 cells
aggregated into pseudoislets with MIN6 monolayer cells
and mouse and human islets.
Methods MIN6 monolayers, pseudoislets and mouse and
human islets were exposed to glucose, α-ketoisocaproic
acid (KIC), pyruvate, KIC plus glutamine and the phos-
phatidylinositol 3-kinase (PI3K) inhibitors LY294002 or
wortmannin. Insulin secretion (ELISA), cytoplasmic Ca2+
concentration ([Ca2+]c; microfluorometry), glucose oxida-
tion (radiolabelling), the expression of genes involved in
mitochondrial metabolism (PCR) and the phosphorylation
of insulin receptor signalling proteins (western blotting)
were measured.
Results Insulin secretory responses to glucose, pyruvate,
KIC and glutamine were higher in pseudoislets than mono-
layers and comparable to those of human islets. Glucose
oxidation and genes for mitochondrial metabolism were
upregulated in pseudoislets compared with single cells and
monolayers, respectively. Phosphorylation at the inhibitory
S636/639 site of IRS-1 was significantly higher in mono-
layers and dispersed human and mouse cells than
pseudoislets and intact human and mouse islets. PI3K inhi-
bition only slightly attenuated glucose-stimulated insulin
secretion from monolayers, but substantially reduced that
from pseudoislets and human and mouse islets without
suppressing the glucose-induced [Ca2+]c response.
Conclusions/interpretation We propose that islet architec-
ture is critical for proper beta cell mitochondrial metabolism
and IRS-1 signalling, and that PI3K regulates insulin secre-
tion at a step distal to the elevation of [Ca2+]c.
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GSIS Glucose-stimulated insulin secretion
KIC Alpha-ketoisocaproic acid
PDX1 Pancreatic and duodenal homeobox 1
PI3K Phosphotidylinositol 3-kinase
Introduction
Insulin secreted from the pancreatic beta cell is the main
glucose-lowering hormone. The loss of beta cell function
plays a key role in the development of both type 1 and 2
diabetes mellitus. The beta cell is located in the islets of
Langerhans, which are scattered in the pancreas and com-
prise approximately 1% of the volume of the gland [1]. In
addition to insulin-secreting beta cells, the islets also contain
other hormone-producing cell types, including glucagon-,
somatostatin- and pancreatic polypeptide-secreting cells, as
well as non-endocrine cells [1]. This makes it important to
consider the contribution of non-beta cells in beta cell islet
experimentation.
The relative difficulties of isolating large numbers of
primary islets, and their mixed cell populations, have made
insulin-producing cell lines an important tool in beta cell
research. The mouse-derived insulinoma MIN6 cell line is
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glucose-responsive [2], although the response is modest,
with a typically twofold to fourfold rise in glucose-
stimulated insulin secretion (GSIS) [3]. A larger secretory
response to a glucose challenge depends on the location of
the beta cell in the islet [4]. When challenged with high
glucose levels, dispersed islet cells secrete less insulin than
beta cells within the intact islet [5]. Interestingly, when
dispersed islet cells were allowed to reaggregate into islet-
like structures, so-called pseudoislets, much of the secretory
capacity was regained [6]. The strategy of allowing cells to
aggregate was also attempted with MIN6 cells, which form
cell clusters the size of primary islets [7]. Despite containing
only insulin-producing cells, these MIN6 pseudoislets
showed enhanced glucose responsiveness compared with
MIN6 cells cultured in monolayers [7].
In the present study, we characterised the detailed dy-
namic insulin secretory response of MIN6 pseudoislets to
different metabolisable and non-metabolisable secreta-
gogues. The secretory phenotype was compared not only
with that of MIN6 cells grown in monolayers, but also with
that of human and mouse islets. We demonstrate that the
superior secretory characteristics of MIN6 cells aggregated
to form pseudoislets compared with MIN6 monolayers
depended on mitochondrial metabolism and was related to
differences in IRS-1 phosphorylation.
Methods
Cell culture Mouse insulinoma MIN6 monolayer cells were
cultured in 250 ml tissue culture flasks (Becton Dickson
Labware, Franklin Lakes, NJ, USA) at 37°C (95% O2 and
5% CO2) in DMEM (Invitrogen, Paisley, UK) as previously
described [3]. MIN6 pseudoislets were prepared by aggre-
gating 3×106 dispersed cells cultured in Petri dishes made
of non-adherent plastic (Becton Dickson Labware) for 3–
5 days using the same culture condition as for monolayers
[7]. All experiments were performed between passages 20
and 30. Human islets were cultured for 4–8 days before
experiments in CMRL medium containing 5.5 mmol/l glu-
cose and supplemented with 10% FBS, 1% L-glutamine,
100 U/ml penicillin and 100 μg/ml streptomycin. Islets from
the pancreases of C57Bl/6 mice were isolated using colla-
genase. The mouse islets obtained were cultured for 2 days
in RPMI 1640 (Invitrogen) medium containing 11.1 mmol/l
glucose supplemented with 10% FBS, 100 units/ml penicil-
lin and 100 μg/ml streptomycin.
To prepare the dispersed cells, groups of 100 human and
mouse islets were dispersed in 0.5% trypsin for 10–12 min
and 3–5 min, respectively, and then treated with DNase I
(Qiagen GmbH, Hilden, Germany) for 2 min. The resulting
cell suspensions were placed in poly-L-lysine-coated plates
and cultured for 48 h in the respective culture medium. The
use of human and mouse islets was approved by the local
ethical committees (Dnr 2010/006 for human islets and Dnr
C106/11 for mouse islets).
Insulin secretion Insulin secretion was measured from
MIN6 monolayers and MIN6 pseudoislets as well as mouse
and human islets. For static incubation experiments, 105
MIN6 cells were seeded into 12-well tissue culture plates
(Becton Dickson Labware) and cultured for 3 days. The
cultured monolayer cells or groups of 20 pseudoislets or
human islets were preincubated for 60 min at 37°C in 1 ml
KRB HEPES buffer consisting of 130 mmol/l NaCl,
4.8 mmol/l KCl, 1.2 mmol/l MgSO4, 1.2 mmol/l KH2PO4,
1.2 mmol/l CaCl2, 5 mmol/l NaHCO3 and 5 mmol/l HEPES,
titrated to pH 7.4 with NaOH and supplemented with
1 mg/ml BSA and 2 mmol/l glucose. Subsequently, the cells
were incubated in 1 ml KRB HEPES buffer containing
either 2 or 20 mmol/l glucose for 30 min at 37°C. Aliquots
(200 μl) of medium were collected for determination of
insulin secretion. Total protein was measured as previously
described [3].
Insulin secretion was also measured dynamically from
monolayer cells, groups of 20 pseudoislets and human and
mouse islets by perifusing in the presence of 2 and 20 mmol/l
glucose as previously described [8]. Individual pseudoislets
and human islets were also perifused in 2 and 20 mmol/l
glucose. For the dynamic insulin measurement, 5×104
MIN6 cells were attached to the central part of poly-L-lysine-
coated coverslips and cultured for 3 days. The samples were
collected at 2 mmol/l glucose during either 10 min for indi-
vidual islets or 20 min for other preparations. Subsequently,
the medium was exchanged to either 20 mmol/l glucose,
2 mmol/l pyruvate, 20 mmol/l alpha-ketoisocaproic acid
(KIC), 10mmol/l KIC plus 10mmol/l glutamine, or 30mmol/l
KCl, and sample collection was continued for another 20 min.
In some experiments, LY294002 (50 μmol/l) or wortmannin
(100 nmol/l for monolayers, pseudoislets and mouse islets;
1 μmol/l for human islets) was introduced into the perifusion
medium 30 min prior to sampling and was present throughout
the experiment. Insulin wasmeasured by ELISA as previously
described [8].
Simultaneous measurements of insulin and cytoplasmic
Ca2+ concentration For simultaneous measurements of in-
sulin and cytoplasmic Ca2+ concentration ([Ca2+]c),
pseudoislets were loaded with 1 μmol/l Fura-2 LR
acetoxymethyl ester (TEFLabs, Inc., Austin, TX, USA) by
incubating them for 60 min at 37°C in KRB HEPES buffer
containing 2 mmol/l glucose and 1 mg/ml BSA. After rins-
ing, groups of islets were allowed to attach to the central part
of poly-L-lysine-coated coverslips. The chamber was placed
on the stage of an inverted microscope (Eclipse TE2000U;
Nikon, Tokyo, Japan). The pseudoislets were perifused for
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60 min with 2 mmol/l glucose in KRB HEPES buffer
supplemented with 1 mg/ml BSA at 37°C at a rate of
160 μl/min. [Ca2+]c was recorded by dual wavelength fluo-
rometry as previously described [9]. During the [Ca2+]c
recordings, the perifusate was collected in 1 min intervals
for subsequent insulin measurements.
To measure the effect of phosphatidylinositol 3-kinase
(PI3K) inhibition, the attached pseudoislets were perifused
for 30 min in 2 mmol/l glucose. Wortmannin (100 nmol/l) or
LY294002 (50 μmol/l) was subsequently added and
perifusion continued for another 30 min before [Ca2+]c
was measured and fractions of perifusate were collected
for insulin measurement in the continued presence of the
inhibitors.
Western blotting To determine the levels of specific pro-
teins, western blotting was performed on MIN6 monolayers,
MIN6 pseudoislets and human and mouse islets with some
modifications as previously described [3]. Immunoblotting
was conducted with antibodies against IRS-1, IRS-2, phos-
phorylated (p)-IRS-1 S636/639, p-IRS-1 S612, p-IRS-1
S307, p-Akt (S473), p-Akt (T308), p-S6 ribosomal protein
(S235/236), total Akt, total S6 ribosomal protein, pancreatic
and duodenal homeobox 1 (PDX1; Cell Signaling, Danvers,
MA, USA), glucokinase, GLUT2 and actin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The immunoreac-
tive bands were imaged with the Fluor-S MultiImager MAX
(Bio-Rad, Hercules, CA, USA) and quantified with Quanti-
ty One software (Bio-Rad).
mRNA expression by real-time PCR Total RNA was
extracted from MIN6 monolayers and pseudoislets using
the RNeasy Mini Kit (Qiagen GmbH). The reverse tran-
scription reaction was performed with 1 μg total RNA using
RT2 First-Strand Kit (Qiagen GmbH). The cDNA obtained
was processed by quantitative real-time reverse transcriptase
PCR of 84 genes involved in the mitochondrial electron
transport chain and oxidative phosphorylation complexes,
and 12 housekeeping genes including internal controls using
the RT2 Profiler PCR Array kit (RT2 Profiler PCR Array
Mouse Mitochondrial Energy Metabolism, PAMM-008;
Qiagen GmbH) and a Stratagene Mx3000p real-time PCR
system (Stratagene, La Jolla, CA, USA). The ΔΔCt-based
fold change in pseudoislets compared with monolayers was
obtained by uploading the raw threshold cycle data to an
integrated web-based software package (RT2 Profiler PCR
Array Data Analysis version 3.5; Qiagen GmbH) for the
PCR array system, using the following formula: fold
change ¼ 2−ΔΔCt , where ΔΔCt=ΔCt (pseudoislets)−ΔCt
(monolayers), and ΔCt=Ct (gene of interest)−Ct (average of
housekeeping genes). Based on PCR array results, some genes
were validated by real-time PCR. The real-time PCR product
was quantified by measuring SYBR Green (Agilent
Technologies, Santa Clara, CA, USA) fluorescent dye incor-
poration with ROX dye reference and normalised to the
housekeeping genes β-actin (Actb), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), hypoxanthine guanine
phosphoribosyl transferase (Hprt) and heat shock protein
90 kDa alpha (cytosolic), class B member 1 (Hsp90ab1).
The primers used are listed in electronic supplementary ma-
terial (ESM) Table 1.
Glucose oxidation rate MIN6 monolayer cells and
pseudoislets were harvested, in triplicate per observation,
and transferred to incubation vials containing KRB HEPES
buffer, supplemented with 20 mmol/l glucose containing
(15.5 GBq/mol) D-[U-14C]glucose. The vials were incubated
for 90 min at 37°C under an atmosphere of 95/5% O2/CO2,
with slow shaking. Metabolism was arrested by adding
17 μmol/l antimycin A. Subsequently, the released la-
belled 14CO2 was trapped in 250 μl hyamine hydroxide
during incubation at 37°C for 2 h, and the radioactivity
was measured by liquid scintillation counting. Cell num-
bers in aliquots of the harvested MIN6 monolayers were
counted in a Becton Dickinson FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA, USA). As
for the pseudoislets, triplicate groups of 50 islets
harvested in parallel to those incubated with labelled
glucose were dispersed as described above, and the cell
number was counted in the flow cytometer. The glucose
oxidation rates were subsequently expressed per number
of cells.
Data analysis Results are presented as means±SEM. Sta-
tistical significance for the difference between two condi-
tions was analysed using the Student’s t test. Multiple
comparisons between different groups were assessed using
ANOVA followed by Bonferroni’s post hoc test. A value p<
0.05 was considered statistically significant.
Results
GSIS In static incubation, pseudoislet insulin release in-
creased approximately sixfold when the glucose concentra-
tion was raised from 2 to 20 mmol/l glucose, whereas for the
monolayers it doubled (Fig. 1). The magnitude of the secre-
tory response of human islets was similar to that of the
MIN6 pseudoislets.
Perifusion of individual MIN6 pseudoislets in the pres-
ence of 2 mmol/l glucose showed insulin oscillations with a
periodicity of 4.3±0.3 min, which were similar to those
observed for human islets (4.1±0.4 min) (ESM Fig. 1).
Augmentation of the glucose concentration to 20 mmol/l
increased the amplitude of the insulin pulses without
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altering the periodicity of the pseudoislets and human islets
(ESM Fig. 1).
Insulin secretion dynamics in response to nutrient and
depolarising stimuli Dynamic insulin secretion from
pseudoislets in response to 20 mmol/l glucose, pyruvate,
KIC, KIC in combination with glutamine, and high KCl
was analysed and compared with that generated from mono-
layer cells and human islets (Fig. 2, Table 1). Secreted
insulin level was determined in the presence of 2 mmol/l
glucose for 10 min prior to the elevation of glucose or the
introduction of other secretagogues (basal), during the first
10 min after stimulation, corresponding to first-phase insu-
lin secretion and for ten subsequent minutes corresponding
to second-phase insulin secretion. A rise in the glucose






























Fig. 1 Insulin secretion from MIN6 monolayers (white bars), MIN6
pseudoislets (grey bars) and human islets (black bars) exposed to 2 or
20 mmol/l glucose for 30 min. The level of insulin released to the
medium was measured and normalised to protein level. Results are
means±SEM of five separate experiments. *p<0.05 compared with
2 mmol/l glucose; †p<0.05 compared with pseudoislets









































































































































Fig. 2 Insulin secretion from
monolayers (dotted line) and
groups of pseudoislets (solid
line) and human islets (dashed
line) in the presence of glucose
(Glu) (a), pyruvate (Pyr) (b),
KIC (c), KIC plus glutamine
(d), or a high concentration of
KCl (e). Insulin released to the
media was measured and
normalised to protein level.
Results are representative of
five separate experiments
1560 Diabetologia (2013) 56:1557–1568
both the first and second phases of insulin secretion in the
pseudoislets, monolayers and human islets (Fig. 2a, Table 1).
The augmentation of insulin secretion from the pseudoislets
was significantly higher than that from the monolayers and
similar to that observed from human islets.
When 2 mmol/l pyruvate was introduced, a small, initial
and transient increase in insulin secretion was observed for
all preparations (Fig. 2b). In the pseudoislets, but not in the
monolayer cells and human islets, pyruvate induced a sig-
nificant rise in second-phase insulin secretion (Table 1).
KIC (20 mmol/l) induced significant first- and second-
phase insulin release from the pseudoislets but increased
only the second phase of insulin secretion from the mono-
layers. In the human islets, KIC elicited a pronounced rise in
both first- and second-phase insulin secretion. When the
pseudoislets were exposed to 10 mmol/l KIC plus 10 mmol/l
glutamine, first- and second-phase insulin secretion was
somewhat augmented compared with secretion observed in
the presence of KIC alone (Fig. 2d, Table 1). In monolayer
cells, the combination caused a small but significant first-
phase insulin secretion. In human islets, the combination
elicited an accentuated first-phase and second-phase insulin
secretion. In the pseudoislets, depolarisation by KCl caused
a prompt transient response involving only first-phase se-
cretion (Fig. 2e, Table 1). A similar but more pronounced
first-phase secretory response was observed in human islets.
In contrast, monolayer cells showed a significant increase in
the second-phase insulin secretory response as well
(Table 1).
Expression of genes related to mitochondrial respiration
and electron transport To investigate how genes encoding
components of the mitochondrial electron transport and
oxidative phosphorylation complex were affected in the
pseudoislets and MIN6 monolayers, the transcript levels of
84 genes were determined where 77 genes were expressed
in both pseudoislets and monolayer cells; a majority (76%)
of the genes showed a 1.4-fold or more increase in the
pseudoislets compared with the monolayers (Table 2).
Genes that showed at least a twofold up- or downregulation
in the array were also validated by quantitative RT-PCR
(Table 2).
Glucose oxidation MIN6 pseudoislets had a markedly
higher glucose oxidation rate at 20 mmol/l glucose (3.57±
0.63 [pmol glucose/cell×90 min]) compared with cells
growing in monolayers (1.09±0.34 [pmol glucose/cell×
90 min]) (p<0.006 using an unpaired Student’s t test; n=6
in both groups). The technique did not allow a direct com-
parison between pseudoislets and adherent monolayer cells,
and we cannot exclude the possibility that the suspended
cells would have shown a different rate of oxidation com-
pared with the monolayers.
Expression of beta cell proteins Levels of proteins
connected with beta cell differentiation and function were
measured in the pseudoislets, monolayers and human islets.
In agreement with previous reports [7, 10] a similar insulin
content was observed in the pseudoislets and monolayer
cells (ESM Fig. 2). These levels were, however, only half
those obtained for the human islets. Levels of PDX1, glu-
cokinase and GLUT2 did not differ between the mono-
layers, pseudoislets and human islets (ESM Fig. 3). PDX-1
protein and glucokinase mRNA levels have been demon-
strated to be similar in MIN6 cells and mouse islets [11, 12]
In addition, both MIN6 cells and mouse islets express high
levels of GLUT2 mRNA [13].
IRS-1 phosphorylation and PI3K activity The total levels of
IRS-1 in the pseudoislets, as well as the total levels of IRS-2
(data not shown), were no different from those obtained for
Table 1 Insulin secretion from MIN6 monolayer cells, pseudoislets
and human islets in the presence of different secretagogues





Glu 2 mmol/l 5.1±0.8 6.4±0.1 8.4±0.6






Glu 2 mmol/l 6.8±0.2 6.3±0.8 11.5±3.2
Pyr first phase 8.4±0.2 11.3±3.7* 14.7±1.3†
Pyr second phase 8.0±0.9† 15.7±1.7* 10.7±2.9
Glu 2 mmol/l 7.1±0.4 8.7±1.6 16.7±6.2
KIC first phase 7.9±0.3† 21.5±2.5* 42.9±10.2*†
KIC second phase 11.9±0.6* 15.3±2.3* 39.3±14.5*†
Glu 2 mmol/l 7.9±0.2 7.1±0.16 14.4±4.6
KIC + Gln first phase 13.6±0.5* 17.2±2.3* 59.0±3.5*†
KIC + Gln second
phase
11.9±0.5*† 20.5±2.5* 43.2±13.8*†
Glu 2 mmol/l 4.4±0.1 8.5±0.61 13.0±4.5
KCl first phase 10.1±0.8* 15.2±0.3* 37.8±8.9*†
KCl second phase 12.1±0.3* 7.2±2.7 6.1±0.6*
Results are means±SEM of between five and eight separate experi-
ments, which were obtained by calculating the area under the curve
from each group of the experiments in Fig. 3
Cells and islets were perifused in the presence of 2 or 20 mmol/l
glucose (Glu), 2 mmol/l pyruvate (Pyr), 20 mmol/l KIC, and
10 mmol/l KIC plus 10 mmol/l glutamine (Gln) or 30 mmol/l KCl.
Secreted insulin was measured for 10 min at 2 mmol/l glucose and in
the initial (first phase) and subsequent (second phase) 10 min after the
introduction of secretagogues
*p<0.05 compared with 2 mmol/l glucose; † p<0.05 compared with
pseudoislets
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the monolayer cells (Fig. 3a). Levels of the inhibitory phos-
phorylation at S636/639 of IRS-1 were lower in pseudoislets
than monolayer cells (Fig. 3b), but no differences were
observed for inhibitory sites S307 and S612 (data not
shown). We also measured whether S636/639 phosphoryla-
tion affected PI3K activity by measuring the level of Akt
phosphorylation at T308 as this site was reported to corre-
late with PI3K activity in other cell types [14, 15]. In MIN6
monolayers, phosphorylation of Akt at site T308 was sig-
nificantly reduced compared with that seen in the
pseudoislets (Fig. 4). When phosphorylation of IRS-1 at
S636/639 was measured in intact and dispersed human and
mouse islets, levels were lower in intact islets than dispersed
cells (Fig. 3d,f).
To determine whether the differences in p-IRS-1 at
S636/639 were contributing to the observed differences in
Table 2 Expression of mito-
chondrial respiration and elec-
tron transport genes in MIN6
monolayer cells and MIN6
pseudoislets
Results are means±SEM of
four separate experiments
Differential mRNA expression
levels of genes encoding
the components of mitochondrial




by PCR array and validated by
quantitative RT-PCR (qRT-PCR)














Lhpp 1.4658 Ndufa7 2.3978 3.10±0.42
Atp4a −1.1394 Ndufa8 2.0163 1.85±0.13*
Atp5a1 1.8554 Ndufab1 −2.2788 1.92±0.34*
Atp5b 1.7553 Ndufb10 2.073 1.96±0.35*
Atp5c1 1.7432 Ndufb2 1.2939
Atp5d 1.6955 Ndufb3 1.2156
Atp5f1 1.8046 Ndufb4 1.5175
Atp5g1 1.2498 Ndufb5 1.4557
Atp5g2 1.8046 Ndufb6 1.6264
Atp5g3 2.0874 1.61±0.08* Ndufb7 1.4658
Atp5h 1.3395 Ndufb8 1.6955
Atp5j 1.7798 Ndufb9 1.9208
Atp5j2 1.6378 Ndufc1 2.0303 1.88±0.34*
Atp5o 1.7073 Ndufc2 1.7675
Atp6v0a2 1.5602 Ndufs1 −1.1878
Atp6v1c2 3.4623 2.48±0.59* Ndufs2 1.1032
Bcs1l 1.7675 Ndufs3 1.7922
Cox11 2.2372 1.73±0.18* Ndufs4 −1.0485
Cox4i1 2.6239 2.50±0.69* Ndufs5 1.1742
Cox5a 1.1421 Ndufs6 2.0445 3.58±0.83*
Cox5b 1.6264 Ndufs7 2.2528 2.54±0.47*
Cox6a1 1.5281 Ndufs8 1.9885
Cox6a2 –3.383 −2.37±0.28* Ndufv1 2.0874 3.17±0.20*
Cox6b1 1.4257 Ndufv2 2.3648 2.42±0.35*
Cox6b2 1.9885 Ndufv3 2.0587 4.41±0.56*
Cox6c 1.8172 Oxa1l 2.2842 2.14±0.38*
Cox7a2 1.1824 Ppa1 −1.8382
Cox7a2l 2.9317 3.17±0.70* Ppa2 1.285
Cox7b 1.571 Sdha 2.073 1.56±0.17*
Cox8a 2.1019 1.82±0.31* Sdhb 1.4061
Cox8c 1.6955 Sdhc 1.4159
Cyc1 1.285 Sdhd 1.8298
Ndufa1 1.9476 Uqcr11 1.2326
Ndufa10 1.507 Uqcrc1 1.9612
Ndufa2 1.7073 Uqcrc2 1.9612
Ndufa3 1.604 Uqcrfs1 1.8683
Ndufa4 1.2326 Uqcrh 2.1166 3.5±0.6*
Ndufa5 1.8298 Uqcrq 1.8426
Ndufa6 2.3161 2.77±0.52*
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secretory patterns via PI3K, we measured insulin secretion in
the presence of the PI3K inhibitors LY294002 and
wortmannin. PI3K inhibition was further studied by measur-
ing the phosphorylation of Akt. LY294002 (50 μmol/l)
blocked Akt phosphorylation in all preparations. Similar re-
sults were obtained with 50 nmol/l wortmannin inMIN6 cells,
pseudoislets and mouse islets, whereas 1 μmol/l wortmannin
was required to obtain inhibition in human islets (data not
shown). The inhibitor LY294002, which was introduced
30 min prior to glucose elevation, decreased GSIS from the
pseudoislets and human islets but did not affect the already
low secretion from the monolayer cells during static incuba-
tion (ESM Fig. 4). In dynamic measurements, basal insulin
secretion from pseudoislets, monolayer cells and human and
mouse islets perifused in the presence of 2 mmol/l glucose
was not affected by either LY294002 or wortmannin (Fig. 5,
Table 3). When the glucose concentration was increased to
20 mmol/l, insulin secretion from the pseudoislets and human
and mouse islets exposed to either of the inhibitors was
significantly reduced in both the first and second phases
(Fig. 5b–d, Table 3). In contrast, a reduction in the first but
not the second, phase of GSIS was observed in monolayer
cells (Fig. 5a, Table 3). Total levels of phosphorylation of Akt
and S6 ribosomal protein, which were located downstream of
PI3K, did not differ between monolayers and pseudoislets
(data not shown). When MIN6 monolayers and pseudoislets
were treated with LY294002 for 60 min, an increased level of
IRS-1 phosphorylation at S636/639 was observed in
pseudoislets compared with monolayer cells (Fig. 6), but no
differences were observed at S307 and S612 (data not shown).
Next, we investigated the extent to which the reduction in
GSIS observed in the pseudoislets exposed to PI3K inhibi-
tors involved alterations in [Ca2+]c. In control pseudoislets,
a rise in the glucose concentration from 2 to 20 mmol/l
elicited a transient decrease in [Ca2+]c followed by a marked
increase that peaked within 2 min after the elevation of
glucose (Fig. 7a, Table 4). After the initial peak, [Ca2+]c



















Fig. 4 Levels of Akt phosphorylated at T308 were measured by
western blotting in MIN6 pseudoislets (PI) and monolayers (MO).
Protein levels were normalised to actin for Akt, and total Akt
for p-Akt (T308). Results are means±SEM of four separate ex-





















































































































Fig. 3 Levels of total IRS-1 and IRS-1 phosphorylated at S636/639
(p-IRS-1) were measured by western blotting in MIN6 pseudoislets
(PI) and monolayers (MO) (a,b), human islets (HU-I) and dispersed
human islets (HU-D) (c,d), and mouse islets (MOU-I) and dispersed
mouse islets (MOU-D) (e,f). Protein levels were normalised to actin for
IRS-1, and total IRS-1 for p-IRS1 (S636/639). Results are means ±
SEM of four or five separate experiments. *p<0.05 compared with
pseudoislets or intact islets
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(∼2/min) appeared. The [Ca2+]c response was paralleled by
a pronounced initial insulin secretory peak followed by
oscillatory insulin levels (Fig. 7a). In pseudoislets pretreated
with LY294002, a blunted GSIS was paralleled by a [Ca2+]c
response that was similar to control but with lower basal
[Ca2+]c and a higher frequency of the glucose-induced os-
cillations (Fig. 7b, Table 4). [Ca2+]c was also recorded in
pseudoislets pretreated with wortmannin. Although this
drug markedly reduced insulin secretion (Fig. 5b), it had
no effect on [Ca2+]c (Table 4). The effects of acute inhibition
of PI3K on [Ca2+]c were also investigated in the
pseudoislets. While LY294002 markedly accelerated the
[Ca2+]c oscillations (Fig. 7c), there was no effect of
wortmannin (Fig. 7d).
















































































































Fig. 5 Glucose (Glu)-
stimulated insulin secretion
from MIN6 monolayers (a),
pseudoislets (b), human islets
(c) and mouse islets (d) in the
absence (solid line) or presence
of the PI3K inhibitors
wortmannin (grey dotted line)
or LY294002 (black dashed
line). Insulin released to the
medium was measured and
normalised to protein. Results
are representative of four or five
separate experiments
Table 3 Effects of PI3K inhibition on GSIS from MIN6 monolayer cells, pseudoislets and human and mouse islets
PI3K inhibitor Insulin secretion [fmol (μg protein)−1]
Monolayer Pseudoislets Human islets Mouse islets
Glu 2 mmol/l 7.4±2.6 6.2±0.8 8.6±0.3 5.3±0.9
Glu 20 mmol/l first phase 18.2±1.5* 40.1±4.5* 65.1±6.4* 31.5±10.2*
Glu 20 mmol/l second phase 12.7±1.8* 55.5±11.9* 51.7±5.5* 43.5±11.3*
Glu 2 mmol/l + W 5.9±0.6 5.8±0.4 9.7±0.4 9.6±0.9
Glu 20 mmol/l + W first phase 9.4±1.3*† 12.9±0.6*† 20.5±0.5*† 19.3±7.3*†
Glu 20 mmol/l + W second phase 10.8±1.8* 13.2±0.8*† 17.6±0.5*† 22.7±5.2*†
Glu 2 mmol/l + LY 4.4±1.0 8.3±0.3 11.9±2.3 8.3±1.2
Glu 20 mmol/l + LY first phase 11.6±1.9*† 12.6±0.3*† 22.7±3.1*† 23.9±2.7*†
Glu 20 mmol/l + LY second phase 11.4±2.5* 11.5±0.2*† 19.1±2.9*† 27.0±5.2*†
Results are means±SEM of four or five separate experiments, which were obtained by calculating the area under the curve from Fig. 7
Cells and islets, exposed or not to the PI3K inhibitor wortmannin (W) or LY294002 (LY), were perifused. Secreted insulin was measured for 10 min
at 2 mmol/l glucose (Glu) and in the initial (first phase) and subsequent (second phase) 10 min after raising the glucose concentration to 20 mmol/l
*p<0.05 compared with 2 mmol/l glucose; † p<0.05 compared with control
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Discussion
The question of why beta cells situated in the islet of
Langerhans perform better than separated beta cells was
addressed using insulin-secreting MIN6 cells arranged as
pseudoislets or monolayers [7, 10]. A number of mecha-
nisms, including intercellular communication by direct cell–
cell contact and an exchange of small molecules through
gap junctions and through paracrine effects have been
suggested to explain the phenomenon [7, 10, 16–18]. In-
deed, in MIN6 pseudoislets, the calcium-dependent cell
adhesion molecule E-cadherin and the gap junction protein
connexin 36, which are required for proper insulin secretion,
were upregulated compared with monolayer cells [7, 18]. In
addition, increases in ins1 mRNA levels were higher in the
pseudoislets than the monolayers [19]. In the present study,
MIN6 cells grown as pseudoislets showed a higher secretory
capacity in response to glucose, in agreement with previous
reports [7, 16]. The notion of the insulin secretory charac-
teristics of pseudoislets being similar to those of primary
islets was further strengthened when the detailed secretory
dynamics were investigated in the pseudoislets. Pulsatile
insulin secretion was observed from pseudoislets, with pulse
durations and amplitude regulation by glucose similar to
those observed for primary islets [20–22]. The enhanced
secretory characteristics of MIN6 pseudoislets in the present
study involved both first- and second-phase insulin secre-
tion, which were equally increased compared with the
monolayer cells, in agreement with a previous report [10].
Impaired glucokinase activity and a lowered expression of
GLUT2 have been connected with impaired insulin secretion
[23, 24]. The similar levels of these two proteins observed in
the present and a previous study [25] suggest that the causes
for the reduced secretion observed in monolayer cells lie distal
to the initial steps of glucose metabolism. When pyruvate was
administered extracellularly, the tricarboxylic acid induced
insulin secretion from pseudoislets. The inability of pyruvate
to elicit insulin secretion has been connected with low levels
of the monocarboxylate transporter as well as a low expres-
sion of lactate dehydrogenase in the beta cell [26, 27]. KIC is a
mitochondrial substrate and acts as a potent insulin secreta-
gogue [28]. The keto acid induced both first- and second-
phase of insulin secretion from MIN6 pseudoislets [7]. When
glutamine was also included, insulin secretion was enhanced
from MIN6 pseudoislets but not to the same degree as was
observed for human islets.
In this context, species differences cannot be ruled out.
Direct comparisons of secretory responses between
pseudoislets and mouse islets for some of the secretagogues
used here and in a previous study [16] showed that the
secretory responses were equivalent. For the remaining se-
cretagogues, mouse islet secretory characteristics have been
studied [29, 30] but not directly compared with those of
MIN6 pseudoislets. Rather than performing a direct com-
parison between MIN6 pseudoislets and mouse islets for the
latter secretagogues, we conducted these experiments with
human islets. This choice was based on the fact that there
are no studies in which the secretory characteristics of MIN6
pseudoislets and human islets have been directly compared.
In this comparison, we could not exclude the influence of
non-beta cells in the human islets as such an influence is
present [31] and is exemplified by studies showing that
glutamine can stimulate glucagon secretion [32] and that
pyruvate is preferentially oxidised in non-beta cells in both
mouse [33] and human [34] islets. In addition, the extent to
which alpha cells influence insulin secretion from
pseudoislets has been addressed [35]. Based on these results
and the observation that genes encoding the mitochondrial
electron transport and oxidative phosphorylation complex as
well as glucose oxidation were upregulated in pseudoislets
compared with monolayers, we propose that enhanced mi-
tochondrial metabolism contributed to the improved secre-
tory capacity of cells in the pseudoislets.
In addition to enhanced metabolism, cell aggregation
seems to be associated with alterations in IRS phosphoryla-
tion. Paracrine insulin signalling can be envisaged to be more


























Fig. 6 Levels of IRS-1 phosphorylated at S636/639 (p-IRS-1) were
measured by western blotting and normalised to total IRS-1 in MIN6
monolayers and pseudoislets with or without the PI3K inhibitor
LY294002 (LY). Results are representative of five separate experi-
ments. *p<0.05 compared with control. MO, monolayers; PI
pseudoislets



































































































































































Fig. 7 Glucose-induced changes in [Ca2+]c and insulin secretion in
MIN6 pseudoislets exposed to PI3K inhibitors. Simultaneous record-
ings of [Ca2+]c and insulin release in control (a) or LY294002-treated
(prior to and during perifusion) pseudoislets (b). Changes in [Ca2+]c in
the pseudoislets after acute exposure to LY94002 (c) or wortmannin
(d). Whereas the parallel recordings of insulin and [Ca2+]c are repre-
sentative of three independent experiments, the [Ca2+]c recordings are
representative of 26 (a), 13 (b), 7 (c) and 8 (d) pseudoislets, respec-
tively, from between two and eight independent experiments; fluor exc,
fluorescence excitation
Table 4 Effects of PI3K inhibition on glucose-induced [Ca2+]c responses in MIN6 pseudoislets
Measurement Control (n=26) LY pretreatment (n=13) W pretreatment (n=6)
Basal level (nmol/l) 118±5 88±9* 102±5
Initial lowering (nmol/l) 16±4 7±1 15±1
Response delay (min) 1.37±0.03 1.52±0.09 1.34±0.06
Glucose-induced peak amplitude (nmol/l) 133±11 134±25 176±12
Average stimulated level (nmol/l) 180±4 148±18 199±7
Oscillation frequency (min−1) 2.18±0.09 8.68±0.56* 2.74±0.06
Results are means±SEM for the number of pseudoislets indicated
[Ca2+ ]c was measured in pseudoislets during an increase in the glucose concentration from 2 (basal) to 20 (stimulated)mmol/l in the absence
(control) or presence of LY294002 (LY) or wortmannin (W). Basal [Ca2+ ]c, the magnitude of the glucose-induced initial lowering of [Ca
2+ ]c, the
time between the elevation of the glucose concentration and the increase in [Ca2+ ]c, the amplitude of the initial glucose-induced increase in [Ca
2+ ]c,
the average [Ca2+ ]c under stimulated conditions as well as the frequency of glucose-induced [Ca
2+ ]c oscillations were quantified for each
pseudoislet
*p<0.05 compared with control
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structures, and we therefore wanted to investigate the insulin
signalling pathway. Insulin secreted from beta cells binds to
the insulin receptor, from which the signal is transduced via
IRSs. The IRS proteins have multiple effects on the beta cell,
including on survival via the PI3K/Akt pathway and on insu-
lin gene transcription via PI3K/mTOR/p70s6 kinase [36–38].
It has been reported that manipulation of IRS-1 levels affects
both the secretion and synthesis of insulin [39, 40]. Although
we observed no significant differences in the total levels of the
IRS proteins in the present study, levels of the inhibitory serine
phosphorylation site S636/S639 of IRS-1 were higher in
monolayers than pseudoislets. The differential IRS-1 phos-
phorylation at site S636/639 is also proposed to contribute to
the increased insulin secretion observed with pseudoislets and
monolayer cells. Such serine/threonine phosphorylations un-
couple the IRS proteins from their upstream and downstream
effectors [41].
In human skeletal muscle cells, increased S636 phos-
phorylation of IRS-1 led to a reduced association of IRS-1
with PI3K [42]. A similar mechanism may be present in beta
cells, since inhibitors of PI3K significantly reduced first-
phase insulin secretion from pseudoislets and human islets
but had only minor effects on the secretory patterns of
monolayer cells. In accordance with this finding, PI3K
inhibition has previously been reported to decrease the first
phase of insulin secretion from MIN6 monolayers and
mouse islets [43]. In contrast, other studies have suggested
that PI3K inhibition results in increased GSIS [44–47].
Differences in experimental design may account for some
of the discrepancy. In support for a role of PI3K as a positive
regulator of insulin secretion, mouse models lacking expres-
sion of PI3K regulatory subunits [48] or of the catalytic
subunit of the type 1B PI3K isoform [49] show reduced GSIS.
PI3K inhibition does not, however, affect glucose metabolism
[44, 50]. Our study showed that the suppression of insulin
secretion by PI3K inhibitors could not be explained by a
reduction in [Ca2+]c, and PI3K seems to act at a distal step
of the secretory process. Accordingly, wortmannin had no
influence on the [Ca2+]c responses, and the increased
frequency of [Ca2+]c oscillations caused by LY294002 is
probably related to the ability of this compound to block
voltage-gated K+ channels (Kv channels) in β-cells [44].
Acute inhibition of PI3K by wortmannin has previ-
ously been demonstrated not to have any effect on
glucose metabolism or ATP content [44, 50]. Thus,
there is no evidence for a direct causal link between
the changes in metabolism and IRS-1 phosphorylation
observed between MIN6 pseudoislets and monolayer
cells. In conclusion, the present study indicates that
enhanced mitochondrial metabolism and the differential
phosphorylation of IRS-1 contribute towards the en-
hanced secretory capacity of beta cells situated in islets
compared with dissociated beta cells.
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